Type: 3CL protease inhibitor created through joint research between Hokkaido University and Shionogi. S-217622 is designed to suppress the replication of SARS-CoV-2 by selectively inhibiting 3CL protease.
2021 Status: S-217622 Shows Safety in Phase I Trial—Shionogi said October 21 that S-217622 showed itself to be safe and well tolerated in a Japanese Phase I trial, a single ascending dose study to healthy Japanese subjects. The once-daily oral dosing of S-217622 was predicted to exceed the target concentration required for the viral reduction effect from the non-clinical studies, Shionogi said.
The company also reported results from non-clinical studies in which S-217622 showed in vitro antiviral activity against a broad range of strains, including the Delta strain. A dose-dependent viral reduction effect of S-217622 was seen in multiple animal studies, while S-217622 showed a good drug metabolism and pharmacokinetics profile supporting oral dosing, the company said without furnishing details.
“Based on these results, S-217622 has the potential to reduce SARS-CoV-2 viral load with once-daily oral administration,” the company stated.
COVID-19: 300 Candidates and Counting
To navigate through the >300 potential therapeutic and vaccine options for COVID-19, GEN has grouped the candidates into four broad categories based on their developmental and (where applicable) clinical progress:
● FRONT RUNNER – the most promising therapeutics/vaccines based on clinical progress, favorable data or both.
● DEFINITELY MAYBE – earlier phases with promising partners, or more advanced candidates in development that have generated uneven data.
● KEEPING AN EYE ON… – interesting technology, attracting notable partners, or both, but preliminary data.
● TOO SOON TO TELL – longshots pending additional experimental and/or clinical data.
GEN has also tagged the most common treatment types: